Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
Authors:
Open Access
- 22 September 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 64 (1) , 142-153
Abstract
Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns and survival in the CCRT+D and CCRT cohorts. We conducted a multicenter, retrospective study in Japan. Patients who received CCRT for stage III NSCLC were included in this study. Of 178 eligible patients, 136 were in the CCRT+D and 42 were in the CCRT cohorts. Locoregional recurrence (LR), LR plus distant metastases (DM), and DM were observed in 20.6%, 8.8%, 27.9% of the CCRT+D, and 26.2%, 16.7% and 33.3% of the CCRT cohorts, respectively. In-field recurrence was the most common LR pattern in both cohorts. Squamous cell carcinoma and PD-L1 expression < 1%, and female sex and EGFR mutations were significantly associated with an increased risk of LR and DM. In patients with any risk factors for LR, the incidence of LR was similar in the CCRT+D and CCRT (39.5% vs 45.5%). The 24 month progression-free survival (PFS) and overall survival (OS) were 40.3% and 69.4% in the CCRT+D and 24.7% and 61.0% in the CCRT cohorts, respectively. Poor performance status and no consolidation durvalumab were significantly associated with shorter PFS. There was a significant difference in PFS between the CCRT+D and CCRT in the propensity score-matched cohort (HR = 0.51, P = 0.005). In conclusion, consolidation durvalumab decreased both LR and DM, and significantly improved PFS. However, in-field recurrence was still a major problem, as well as DM.Keywords
Funding Information
- Kyoto Radiation Oncology Study Group
This publication has 27 references indexed in Scilit:
- A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non–Small Cell Lung Cancer: A Phase I StudyJournal of Thoracic Oncology, 2017
- Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617JNCI: Journal of the National Cancer Institute, 2016
- Dose escalation in lung cancer: have we gone full circle?The Lancet Oncology, 2015
- Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasisClinical & Experimental Metastasis, 2014
- EGFR Mutation and Brain Metastasis in Pulmonary AdenocarcinomasJournal of Thoracic Oncology, 2014
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 2004